Actively Recruiting
Observational Study of Safety and Quality of Life in Patients Treated with Innovative Anticancer Drugs at Rafael Institute
Led by Institut Rafael · Updated on 2024-10-01
300
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of innovative and costly anticancer drugs on patients treated at the Rafael Institute, focusing on both safety and effectiveness in real-world use. The study also aims to measure patients quality of life, recognizing that treatment side effects and symptoms impact well-being. This research supports a patient-centered approach, emphasizing personalized and continuous care by a multidisciplinary team to improve overall treatment management. This observational study involves collecting data through standardized and validated self-questionnaires, including the European Organisation for Research and Treatment of Cancer EORTC QLQ-C30 and EQ-5D-5L, along with NCI-PRO-CTCAE questionnaires. Patients receiving non-pharmacological care at the Rafael Institute and treated with selected anticancer drugs are followed over time to document treatment effects and quality of life. Participants will be observed for up to 36 months, with assessments of overall survival, progression-free survival, and incidence of adverse events. Quality of life measurements are taken every six months to track changes over time. Data collection focuses on patients subjective health perceptions, symptoms, and treatment impact, supporting better understanding and management of cancer therapies in everyday practice.
CONDITIONS
Brief Title
Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs
Research Team
A
Alain TOLEDANO, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here